Ponesimod Combination Therapy for Simpler Immune Disorder Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphocyte-mediated immune system disorders, such as multiple sclerosis and autoimmune diseases, often require multiple medications with varying dosing regimens, which can be complex and may not achieve optimal efficacy or safety profiles.
Innovation Solution
A pharmaceutical combination of ponesimod and either teriflunomide or leflunomide, administered separately or together, provides a simplified dosing regimen that synergistically reduces lymphocyte counts and ameliorates immune system activation, addressing a range of immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple medications with varying dosing regimens are used to treat lymphocyte-mediated immune system disorders, then treatment efficacy may be achieved, but treatment complexity and dosing regimen complexity increase
Solution Approach 1:
The patent combines ponesimod with teriflunomide or leflunomide into a single pharmaceutical composition, merging two separate medications into one. This allows patients to receive multiple immunomodulating agents through a single dosing action, thereby maintaining treatment efficacy while reducing dosing regimen complexity and improving ease of operation.
2Reliability
If individual medications are used to reduce lymphocyte counts, then treatment efficacy is achieved, but safety profiles may be compromised
Solution Approach 1:
The combination of ponesimod with teriflunomide or leflunomide in a single pharmaceutical composition allows for synergistic immunomodulating effects. The patent demonstrates that this combination achieves superior disease control and improved safety profiles compared to monotherapy, as the combined agents work together to enhance lymphocyte reduction while managing safety concerns through optimized dosing.
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.